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ABSTRACT 
Objective. Regulatory T cells (Tregs) with the plasticity of producing 
proinflammatory cytokine IL-17 have been demonstrated under normal and 
pathogenic conditions. However, it remains unclear whether IL-17-producing Tregs 
lose their suppressive functions because of their plasticity toward Th17 in 
autoimmunity. The aim of this study was to investigate IL-17-producing Tregs from 
patients with rheumatoid arthritis (RA) and characterize their regulatory capacity and 
clinical significance. 
Methods. Foxp3 and IL-17 co-expression were evaluated in CD4+ T lymphocytes 
from RA patients. An in vitro T cell polarization assay was performed to investigate 
the role of proinflammatory cytokines in IL-17-producing Treg polarization. The 
suppressive function of IL-17-producing Tregs in RA was assessed by an in vitro 
suppression assay. The relationship between this Treg subset and clinical features in 
RA patients was analyzed using Spearman’s rank correlation test.  
Results. A higher frequency of IL-17-producing Tregs was present in the peripheral 
blood of RA patients compared with healthy subjects. These cells from peripheral 
blood showed phenotypic characteristics of both Th17 and Treg cells, and suppressed 
T cell proliferation in vitro. Tregs in RA synovial fluid lost suppressive function. The 
Th17 plasticity of Tregs could be induced by IL-6 and IL-23. An increased ratio of 
this Treg subset was associated with decreased levels of inflammatory markers, 
including the erythrocyte sedimentation rate and C-reactive protein level, in patients 
with RA.  
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Conclusion. Increased levels of IL-17-producing Tregs were identified in RA patients. 
This Treg subset with Th17 plasticity in peripheral blood retained suppressive 
functions and was associated with milder inflammatory conditions, suggesting that 
this Treg population works as a negative regulator in RA, but in RA synovial site it 
may be pathogenic. 
Key words: plasticity, regulatory T cell, rheumatoid arthritis, Th17 
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INTRODUCTION 
IL-17-producing CD4+ T cells (Th17 cells) and Foxp3+ regulatory T cells (Treg 
cells) have been implicated in the pathogenesis of various chronic autoimmune 
diseases, including rheumatoid arthritis (RA) [1–4]. Increased Th17 cells mediate 
autoreactive inflammation and tissue destruction during RA development [5–8], 
whereas several types of Treg cells maintain tight regulation of T helper (Th) cells for 
preventing T cell-mediated autoimmunity and inflammatory damage [9–12]. Recent 
studies have revealed a link between Treg and Th17 cells. Treg and Th17 cells may 
develop from the same precursors under distinct cytokine conditions [13], and a 
subset of IL-17-producing CD4+Foxp3+ Treg cells can be generated upon 
polarization by cytokines such as IL-6 [14–16].  
The observed Th17 plasticity of Treg cells has raised the possibility that the 
stability of Foxp3+ Treg cells may play a potential pathogenic role at sites of 
inflammation. Treg cells with the plasticity of producing the proinflammatory 
cytokine IL-17 have been detected in normal human peripheral blood as well as in 
inflamed intestinal mucosa in patients with Crohn’s disease [16, 18]. However, 
conflicting data exist regarding the functions of the IL-17-producing Treg population. 
Previous studies have reported that the induction of IL-17 expression in Treg cells 
under inflammatory conditions was accompanied by impaired or lost suppressive 
function [26, 27]. In contrast, Hovhannisyan et al. showed that IL-17-producing Treg 
cells from patients with Crohn’s disease retained suppressive activity despite their 
increased IL-17 production, although the authors suggested that resident Treg cells 
under inflammatory conditions may convert to IL-17-producing cells and thus 
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potentially contribute to the pathogenesis of the disease [18]. To date, the exact role of 
Treg plasticity in immunoregulation is unclear, and the presence and clinical 
significance of the IL-17-producing Treg subset in RA remains unknown.  
In the present study, we investigated the CD4+ Foxp3+ IL-17-producing Treg 
cell in patients with RA. This Treg population exhibited phenotypic characteristics of 
both Treg and Th17 cells, and retained potent suppressive activity in peripheral blood. 
However, these Treg cells in RA synovial site lost suppressive activity. The expansion 
of this Treg population was promoted by the inflammatory cytokines IL-6 and IL-23, 
which were abnormally elevated in patients with RA. Moreover, the peripheral 
IL-17-producing Treg subset was associated with decreased RA disease activity, 
suggesting that these Treg cells are negative regulators in RA peripheral blood, but 
they might be pathogenic in RA synovial sites.. 
 
MATERIALS AND METHODS  
Flow cytometry  
Isolated PBMCs were stained for CD4 expression using a PE-CF594-labeled 
anti-human-CD4 antibody, for CD127 expression using a PerCP-Cy5.5-labeled 
anti-human-CD127 antibody, and for CD25 expression using a PE-Cy7-labeled 
anti-human-CD25 antibody (all antibodies from BD Pharmingen, San Diego, CA, 
USA). The expression of CTLA-4, IL-10, CD161, and CCR6 was examined using 
FITC-labeled monoclonal antibodies (BD Pharmingen). To analyze cytokine 
production, cells were stimulated and incubated for 5 h with 50 ng/ml phorbol 
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myristate acetate (PMA), 1 µg/ml ionomycin (both from Sigma-Aldrich, Germany), 
and 1 µl/ml GolgiStop (BD Biosciences, Franklin Lakes, NJ, USA). After stimulation, 
the cell surface markers CD4, CD25, and CD127 were stained with the fluorescently 
labeled monoclonal antibodies mentioned above. Next, the cells were fixed and 
permeabilized for 30 minutes at room temperature at dark with the Foxp3 
Fixation/Permeabilization Concentrate and Diluent buffer set (eBioscience). Then the 
cells were stained with PE-labeled anti-human Foxp3 monoclonal antibody 
(eBioscience) and Alexa Fluor 647-labeled anti-human-IL-17A antibody or 
PE-labeled anti-mouse/human RORγt antibody (eBioscience). The cells were 
examined by flow cytometry (BD Aria II flow cytometer), and the data were analyzed 
using FlowJo v5.7 software (Tree Star, Inc., USA). 
 
Other detailed information about sample preparation, experimental and statistical 
methods are available in the Supplementary Materials 
 
RESULTS 
IL-17-producing Treg cells were present in the peripheral blood of patients with 
RA 
To verify the plasticity of Treg cells to produce Th17 under autoimmune 
inflammatory conditions, IL-17 production and Foxp3 expression in CD4+ T cells 
were examined using flow cytometry of PBMCs from patients with RA and healthy 
subjects. IL-17-producing CD4+ Foxp3+ Treg cells were present in patients with RA 
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and healthy controls (Figure 1A), and the frequency of IL-17-producing CD4+ 
Foxp3+ Treg cells was significantly higher in patients with RA than in healthy 
controls (Figure 1B). Notably, in patients with RA, there is no significant correlation 
between IL-17-producing Treg cells and CD4+ Foxp3+ Treg cells (Figure 1C), and 
this IL-17-producing Treg population showed significantly positive correlation with 
Th17 cells (Figure 1D). We further examined the IL-17 producing Treg cell frequency 
in matched synovial fluid and peripheral blood from RA patients, and found that the 
frequency of this Treg subset was significantly elevated in synovial fluid (Figure 1E 
and Supplementary Figure 1).  
A previous study has defined three cell fractions with different functional 
characteristics in CD4+CD25+ Treg cells with CD45RA and Foxp3 expression [21], 
Figure 1F upper panel]. Our study showed that more than 60% of IL-17 producing 
Treg cells were enriched in CD45RA- Foxp3low “non-Treg” fraction, and around 30% 
IL-17 producing Treg cells distributed in CD45RA+ Foxp3low “resting Treg” fraction. 
Few Tregs in CD45RA- Foxp3hi “activating Treg” fraction expressed IL-17 (Figure 
1F lower panel).  
IL-17-producing Treg cells from the peripheral blood of patients with RA 
exhibited phenotypic characteristics of both conventional Th17 and Treg cells  
To examine the phenotypic characteristics of the IL-17-producing CD4+ Foxp3+ 
Treg cells, we used flow cytometry to assess the expression of Foxp3 and surface 
markers or cytokines known to be associated with either Th17 or Treg cells. The 
expression levels of the Treg-associated regulatory molecules CTLA-4 and IL-10 
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were significantly higher in IL-17-producing CD4+ Foxp3+ Treg cells (MFI: 6.11 ± 
0.92 and 4.46 ± 0.39, respectively) than in either conventional CD4+ Foxp3+ Treg 
cells (MFI: 2.77 ± 0.10 and 2.69 ± 0.21, respectively; p < 0.05 for each) or Th17 cells 
(MFI: 3.67 ± 0.48 and 3.25 ± 0.07, respectively; p < 0.05 for each), whereas Foxp3 
expression was slightly but significantly lower in IL-17-producing CD4+ Foxp3+ 
Treg cells than in conventional Treg cells (MFI: 68.74 ± 13.80 vs. 77.88 ± 16.00, p < 
0.05) (Figure 2). CCR6 and CD161 are human Th17 cell markers [24], whereas 
conventional Treg cells express characteristically low levels of CD127 [20]. Similar to 
Th17 cells, IL-17-producing CD4+ Foxp3+ Treg cells expressed higher levels of 
CCR6, CD161, and CD127 compared with conventional Treg cells (CCR6 MFI: 3.40 
± 0.16 vs. 1.86 ± 0.07, p < 0.05; CD161 MFI: 13.99 ± 2.98 vs. 1.86 ± 0.07, p < 0.05; 
CD127 MFI: 32.29 ± 5.68 vs. 13.48 ± 2.36, p < 0.05; Figure 2 A and B). These results 
show that IL-17-producing CD4+ Foxp3+ Treg cells exhibit phenotypes of both 
conventional Th17 and Treg cells. 
Inflammatory cytokines in RA promoted the induction of IL-17-producing Treg 
cells  
To characterize the inflammatory milieu contributing to the plasticity of Treg cells 
in the peripheral blood from patients with RA, we assessed the concentrations of 
different proinflammatory cytokines in serum samples. Serum levels of IL-6 and 
IL-23 were significantly elevated in patients with RA compared with healthy controls 
(IL-23: 32.67 ± 34.50 vs. 1.82 ± 1.51 pg/ml, p < 0.001; IL-6: 157.83 ± 27.07 vs. 21.97 
± 3.52 pg/ml, p < 0.001; Figure 3A).  
Page 10 of 37
http://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
10 
 
Because IL-6 and IL-23 together promote the development and expansion of Th17 
cells [9-11], elevated levels of these two cytokines in the sera of patients with RA may 
also provide the polarizing environment for the expansion of IL-17-producing Treg 
cells. To test this hypothesis, CD4+CD25+ Treg cells from the peripheral blood of 
patients with RA or healthy controls were purified by cell sorting and cultured in vitro 
in the presence of IL-2, IL-1β, and anti-CD3 and anti-CD28 antibody coated beads  
and supplemented with IL-6, IL-23, or both for 5 days. As expected, relatively low 
frequency of IL-17-producing Foxp3+ Treg cells was detected in cultures without the 
addition of polarizing cytokines. In the presence of IL-23, there was a slight but not 
significant increase in the IL-17-producing Treg frequency. However, under the 
polarizing culture condition supplemented with IL-6 or both IL-6 and IL-23, a 
significantly increased IL-17-producing Treg cell frequency was observed (Figure 3B 
and C), implicating the polarizing function of IL-6 and IL-23 and that IL-6 should be 
a major player in the induction of IL-17-producing Treg cells. However, we did not 
observe any significant correlation between the serum levels of these polarizing 
cytokines and the IL-17 producing Treg subset (Supplementary Figure 2). Compared 
to Tregs from RA patients, Tregs from healthy controls showed similar plasticity 
toward Th17 under the same polarizing culture conditions (Figure 3B and C), though 
the IL-17 producing Treg frequencies were modestly lower than those from RA 
patients without statistical significance. We also examined the expression of 
Th17-lineage specific transcription factor RORγt in Treg cells cultured in polarizing 
conditions. The RORgt levels were obviously increased when IL-6 or IL-6 together 
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with IL-23 was added to culture (Figure 3D).      
 
CD161 expression defined IL-17-producing Treg subset 
We found that CD161, a surface marker of Th17 precursor cells [24], was 
dramatically increased on IL-17 producing Treg cells (Figure 2), and it could also be 
used as the surface marker to characterize IL-17 producing Treg cells (Figure 4A). 
With CD161 expression, we sorted CD4+CD25+ Treg cells from RA peripheral blood 
into two subsets: CD4+CD25+CD161+ Treg and CD4+CD25+CD161- Treg (Figure 
4A upper panel). Most IL-17 producing Treg cells were enriched in the CD161+ Treg 
population and few CD161- Treg cells expressed IL-17 (Figure 4A middle panel). 
Besides IL-17 production, the CD4+CD25+CD161+ Treg cells also expressed 
significantly higher RORγt than the CD161- Treg population (Figure 4A lower panel), 
which further confirmed that CD4+CD25+CD161+ Treg population was the IL-17 
producing Treg subset and processed increased plasticity toward Th17. Similar results 
were also obtained in Treg cells from synovial fluid of RA patients and peripheral 
blood of healthy controls (data not shown).  
 
Peripheral IL-17-producing Treg cells from patients with RA retained 
suppressive function in vitro 
We next investigated whether the IL-17-producing Treg cells from patients with 
RA possessed suppressive function. Although IL-17 producing Treg cells expressed 
IL-17, we also observed significantly elevated immunosuppressive molecular IL-10 
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and  CTLA-4 expression in this Treg subset than in conventional Treg cells (Figure 
2B), which implicated the possibility that IL-17 producing Treg cells might play a role 
in immunosuppression. 
By CD161 staining, it was feasible to sort and enrich fresh IL-17 producing Treg 
cells from peripheral blood or synovial fluid. We set up Treg suppression assay with 
CD4+CD25+CD161+ IL-17 producing Treg cells and CD4+CD25+CD161- Treg cells 
from peripheral blood of RA patients and healthy controls as well as these two Treg 
subsets from RA synovial fluid. The CD4+CD25+CD161+ Treg cells and 
CD4+CD25+CD161- Treg cells from both RA and healthy peripheral blood showed 
comparable suppression activity on CD4+CD25- responder T-cell (Tresp) 
proliferation (Figure 4B). In contrast to Tregs from peripheral blood, both CD161+ 
IL-17 producing Tregs and CD161- Tregs from RA synovial fluid did not inhibit 
Tresp proliferation (Figure 4B). This result shows that IL-17-producing Treg cells 
circulating in peripheral blood retained a potent suppressive function to inhibit T cell 
proliferation, but the immunosuppressive activity of Treg cells in RA synovial fluid 
was seriously impaired. 
 
Associations between circulating IL-17-producing Treg cells and RA clinical 
features  
To determine the clinical relevance of IL-17-producing Treg cells in RA, the 
percentages of this Treg subset among CD4+ Foxp3+ Treg cells in the peripheral 
blood were measured in a cohort of 42 patients with RA. The percentages of 
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IL-17-producing Treg cells among CD4+ Foxp3+ Treg cells were negatively 
correlated with ESR (r = –0.50, p < 0.01), CRP (r = –0.32, p = 0.036), and total IgG 
(r = –0.371, p = 0.022) (Figure 5A). There were also weak but significant positive 
correlations between this subset and circulating complement levels (C3, r = 0.33, p = 
0.048; C4, r = 0.32, p = 0.045; Figure 5A), suggesting that C3 and C4 levels would 
decrease with fewer IL-17-producing Treg cells. No significant correlation was found 
with patient age, disease duration, anti-CCP antibody, RF-IgM, RF-IgG, total IgA, 
total IgM, tender joint count, swollen joint count, or DAS28. These correlations 
indicate that the increased ratio of IL-17-producing Treg cells is associated with 
milder inflammation in patients with RA, which suggests that the circulating IL-17 
producing Treg subset plays a negative regulatory role in the autoimmunity of RA. In 
addition, the ratio of IL-17-producing Treg cells was significantly lower in CD4+ 
Treg cells from patients with high RA disease activity (DAS28 > 5.1) than in cells 
from patients with intermediate or low disease activity (DAS28 < 5.1; Figure 5B). 
These results were consistent with our data from in vitro suppressive assays, 
suggesting that circulating IL-17-producing Treg cells in patients with RA retain their 
regulatory function in the inflammatory conditions of RA. 
 
DISCUSSION 
Recent studies have reported plasticity in the differentiation of Treg and Th17 
cells. Foxp3+ Treg cells can be converted into inflammatory cytokine-producing cells 
in the specific inflammatory microenvironment and may potentially contribute to 
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disease pathogenesis [14–20]. However, the contributions of Treg plasticity to the 
pathogenesis of autoimmune diseases require further study. In this study, we report for 
the first time the identification of IL-17-producing CD4+ Foxp3+ Treg cells in 
patients with RA. The frequency of this IL-17-producing Treg population is 
significantly increased in peripheral blood and synovial fluid of RA patients compared 
with that in healthy controls, which suggests that this Treg cell subset is associated 
with RA pathology.  
We evaluated the distribution of IL-17 producing Treg in CD4+CD25+ Treg 
subpopulations defined with different CD45RA and Foxp3 expression by Sakaguchi 
group [21]. The majority of IL-17 producing Treg cells (over 60%) were from the 
CD45RA- Foxp3low “non-Treg” fraction, which was considered transiently and 
unstably expressing Foxp3 and was shown to lack suppressive activity and had Th17 
cell potential [21], while relatively fewer IL-17 producing Treg cells were also 
distributed in the CD45RA+ Foxp3low “resting Treg” fraction (around 30%) and 
CD45RA- Foxp3hi “activating Treg” fraction (less than 10%), both of which stably 
expressed Foxp3 and were suppressive [21]. This result clearly revealed that IL-17 
producing Treg cells derived from different Treg lineages, and Treg plasticity toward 
Th17 existed in all these subpopulations. 
We observed that circulating IL-17-producing Foxp3+ Treg cells in peripheral 
blood exhibited phenotypes of Th17 cells, including IL-17 secretion and elevated 
expression of RORγt, CD161 and CCR6. CD161 has been identified to be an 
important Th17 molecular marker. Nearly all Th17 cells were contained in CD161+ 
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population and originated from CD161+ naïve T cells [24]. In this study, we also 
identified CD161 as the key surface marker to characterize IL-17 producing Treg cells. 
The CD4+CD25+CD161+ Treg subset enriched nearly all of the IL-17 producing 
Treg cells and the RORγt expression was significantly increased in this subset, which 
indicated that the CD161 specifically defined the Treg subset producing IL-17 and 
possessing high plasticity toward Th17.  
Besides the Th17 lineage markers, the IL-17 producing Treg cells from 
peripheral blood of RA patients continued to express the anti-inflammatory factors 
IL-10 and CTLA-4 and to retain functional suppressive activity in vitro. In addition, 
we found a significant negative correlation between this Treg subset in peripheral 
blood and RA inflammation markers (ESR, CRP, total IgG and C3/C4 decreasement), 
which indicated that inflammation and autoimmune responses might be milder with 
increased peripheral IL-17-producing Treg cells in patients with RA. This clinical 
relevance is consistent with the potent suppressive function of RA peripheral 
IL-17-producing Treg cells. Our data are in agreement with the recent finding that 
IL-17-positive Treg cell clones from the inflamed intestinal mucosa of patients with 
Crohn’s disease remained suppressive in vitro [18], and our results support those of an 
in vitro investigation by Walter et al., which showed that the IL-17-producing Treg 
cells induced by RA-related cytokine-activated monocytes in vitro exhibited e hanced 
inflammatory cytokine expression and suppressive function [25]. Together with 
findings from different experimental systems, our study suggests that an increased 
proinflammatory cytokine IL-17-expressing Treg population in peripheral blood acts 
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as a negative regulator in RA development by maintaining or enhancing suppressive 
capacity. 
The IL-17-producing Treg subset exhibits phenotypic characteristics of both Treg 
and Th17 cells. As a result of the overproduction of proinflammatory cytokines in RA, 
it is possible that Treg cells may be skewed toward IL-17-producing Foxp3+ Treg 
cells in the presence of inflammatory mediators, thereby favoring Th17 differentiation 
in patients with RA. Although these cells in peripheral blood could play a regulatory 
role in RA, we cannot exclude the possibility that some cells in some circumstances 
may functionally shift from regulatory T cells to inflammatory effectors expressing 
IL-17 but lost suppressive functions. In this study, we observed increased frequency 
of IL-17 producing Tregs in RA synovial fluid, but there was a seriously loss of Treg 
suppressive activity in RA synovial fluid (Figure 1E and 4B). It is likely that in 
peripheral blood, the pathogenic function of IL-17-producing Foxp3+ Treg cells is 
limited because of their relatively low frequency and retaining suppressive functions. 
However, in RA synovial tissues, proinflammatory cytokines such as TNFα, IL-1, 
IL-6, etc. dramatically increased than in peripheral blood [28, 29]. IL-1 or IL-6 
increase might promote the Treg plasticity toward Th17, leading to elevated IL-17 
producing Treg frequency in synovial fluid. Meanwhile, TNFα overexpression 
disabled Treg suppression in synovial fluid by dephosphorylating Foxp3 [30]. Thus, 
in RA synovial sites, IL-17 producing Treg cells losing suppressive function may act 
more like Th17 cells, which will promote the joint inflammation due to heavily 
impaired suppressive function as well as their IL-17 production and increased 
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frequency. The IL-17-producing Treg subset may remain suppressive in RA peripheral 
blood but contribute to autoimmunity in synovial sites.  
We detected significantly elevated levels of IL-6 and IL-23 in the peripheral 
blood of patients with RA compared with healthy controls. Importantly, both IL-6 and 
IL-23 have been recognized as key contributors to Th17 cell differentiation. IL-6 is 
engaged in polarizing Th17 cell differentiation, whereas IL-23 is critical for Th17 cell 
stabilization and expansion [20, 22, 23]. Therefore, there may be a Th17 cell 
polarizing environment that consists of Th17-related proinflammatory cytokines in 
the periphery blood of patients with RA. In the present study, IL-6 alone or IL-6 and 
IL-23 potently promoted the production of IL-17 by purified CD4+ CD25+ Treg cells 
from both RA and HC peripheral blood in vitro, suggesting that IL-17-producing Treg 
cells may be differentiated from Foxp3+ Treg cells in RA inflammatory conditions. 
Treg cells from healthy controls and RA patients showed similar plasticity toward 
Th17 (Figure 3C), which suggested that there might be no significant intrinsic 
differences in Treg cell sensitivity to polarizing cytokines between RA patients and 
healthy controls. The higher RA peripheral IL-17 producing Treg frequency might be 
attributed to the microenvironment with significantly elevated polarizing cytokines in 
RA peripheral blood. 
In conclusion, our data identified increased IL-17-producing regulatory T cells in 
the presence of elevated IL-6 and IL-23 levels in patients with RA, providing 
evidence that Treg cells with the plasticity of IL-17 expression in autoimmune 
conditions could retain their suppressive capacity. The peripheral Treg cell population 
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with increased Th17 plasticity may still play a role as negative regulator in RA 
autoimmunity, but they lose suppressive activity in synovial sites and may become 
pathogenic. Future investigations regarding this cell population and the development 
of Treg/Th17 plasticity will provide a better understanding of the 
immunopathogenesis of RA.  
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FIGURE LEGENDS 
Figure 1. IL-17-producing Treg cells in peripheral blood from patients with RA and 
healthy controls. The expression of Foxp3 and IL-17 in CD4+ T cells from patients 
with RA and healthy controls was evaluated by intracellular cytokine staining and 
flow cytometry. A. Representative flow cytometric profile showing IL-17 expression 
in CD4+ Foxp3+ Treg cells in patients with RA and healthy controls. B. Four 
independent experiments showed that the percentage of IL-17-producing Treg cells in 
CD4+ Foxp3+Treg cells was significantly higher in patients with RA (n = 12) than in 
healthy control subjects (n = 7). * p < 0.05. RA: patients with RA; HC: healthy 
controls. C. There is no significant correlation between IL-17-producing Treg cells 
and CD4+ Foxp3+ Treg cells in patients with RA. D. The IL-17-producing Treg cells 
were positively correlated with Th17 cells in patients with RA. E. 
there are higher frequency of IL-17-producing Tregs in RA synovial fluid than in 
matched peripheral blood (n=5); SF: synovial fluid; PB: peripheral blood. F. 
Distribution of IL-17 producing Treg cells in Treg fractions defined by CD45RA and 
Foxp3 expression. Numbers on the representative flow cytometry graph indicate 
IL-17 producing Treg numbers in that Treg fraction, percentages in round brackets 
indicate the percentages of IL-17 producing Tregs of that fraction in total IL-17 
producing Tregs of the representative sample. Fr: Fraction; Fr I: CD45RA+Foxp3low 
resting Treg cells; Fr II: CD45RA-Foxp3hi activating Treg cells; Fr III: 
CD45RA-Foxp3low “non-Treg” cells. 
 
Page 24 of 37
http://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
24 
 
 
Figure 2. IL-17-producing Treg cells display phenotypic similarities to both Th17 and 
Treg cells. Surface expression of CTLA-4, CD161, CCR6, and CD127, and 
intracellular expression of Foxp3 and IL-10 were measured in IL-17-producing CD4+ 
Foxp3+ Treg cells. The CD4+ Foxp3+ Treg cells and CD4+IL17+ Th17 cells were 
examined by flow cytometry 5 h after stimulation with phorbol myristate acetate 
(PMA)/ionomycin. The expression levels of the surface markers or cytokines were 
quantified as mean fluorescence intensity (MFI). Data are representative of at least 
five independent experiments (n = 5; *p < 0.05). A. Representative overlayed flow 
cytometric histograms showing expression of CTLA-4, CD161, CCR6, CD127, 
Foxp3 and IL-10 in CD4+ Foxp3+ Treg cells, IL-17-producing Treg cells and 
CD4+IL17+ Th17 cells; red histogram, CD4+ Foxp3+ Treg cells; green histogram, 
IL-17 producing Treg cells; blue histogram, Th17 cells; B. The expression levels of 
the molecular measured above were quantified as mean fluorescence intensity (MFI).  
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Figure 3. Induction of peripheral CD4+ regulatory T cells into IL-17-producing 
CD4+Treg cells under RA inflammatory conditions. IL-6 and IL-23 levels in sera 
from patients with RA and healthy controls were quantified by enzyme-linked 
immunosorbent assay (ELISA). CD4+ T cells were stimulated with either IL-6 or 
IL-23, or both in vitro in the presence of anti-CD3 and anti-CD28 mAb-coated beads, 
IL-2 and IL-1β. The expression of Foxp3 and IL-17 was determined by intracellular 
cytokine staining and flow cytometry. A. IL-6 and IL-23 concentrations in sera of 39 
patients with RA (RA) and 27 healthy controls (HC) were assessed by ELISA (*p < 
0.01). B. IL-17 and Foxp3 expression levels in CD4+CD25+ Treg cells from RA 
patients and healthy controls were examined in the presence or absence of IL-6 or 
IL-23 in vitro with anti-CD3 and anti-CD28 mAb-coated beads, IL-2 and IL-1β. Data 
are representative of three independent experiments. C. The frequencies of 
IL-17-producing Treg cells from RA patients and healthy controls were measured in 
the presence or absence of IL-6 or IL-23 in vitro. Data are from three independent 
experiments (*p < 0.05). D. Comparison of RORγt expression in CD4+CD25+ Treg 
cells in the presence or absence of IL-6 or IL-23 in vitro. Data are representative of 
two independent experiments. 
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Figure 4. IL-17 producing Treg cells were enriched in the CD4+CD25+CD161+ Treg 
subset. CD4+ CD25− effector T (Tresp) cells stained with CFSE were cultured alone 
or with IL-17 producing CD4+CD25+CD161+ Treg cells or CD4+CD25+CD161- 
Treg cells with rare IL-17 production. Tresp cells were stimulated with anti-CD3 and 
anti-CD28 mAb coated beads, and their proliferation in 5 days was determined by 
flow cytometry. A. CD4+CD25+ Treg cells could be isolated into 
CD4+CD25+CD161+ subset and CD4+CD25+CD161- subset. IL-17 producing Treg 
cells were enriched in the CD4+CD25+CD161+ Treg subset. RORgt expression was 
significantly elevated in CD4+CD25+CD161+ Treg cells (*p < 0.05). B. both of the 
CD4+CD25+CD161+ and CD4+CD25+CD161- Treg subsets from peripheral blood 
of RA patients and healthy controls showed comparable suppression activity on 
CD4+CD25- Tresp cell proliferation, while the suppressive activity of 
CD4+CD25+CD161+ and CD4+CD25+CD161- Treg subsets from RA synovial fluid 
was dramatically impaired. Data are representative of 3-5 independent experiments 
(*p < 0.05). RA: patients with RA; HC: healthy controls; Tresp: responder T cell. 
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Figure 5. Negative correlation of IL-17-producing Treg cells with RA disease activity. 
The correlations between the percentage of IL-17-producing CD4+ Foxp3+ Treg cells 
in circulating CD4+ Foxp3+ Treg cells and clinical features of patients with RA (n = 
42) were analyzed by Spearman’s rank correlation test. RA disease activity was 
evaluated by the 28-joint count disease activity score (DAS28), and the 
IL-17-producing CD4+ Foxp3+ Treg cell frequencies were compared between 
patients with high RA disease activity and patients with intermediate and low disease 
activity. A. The ratio of IL-17-producing CD4+ Foxp3+ Treg cells in circulating 
CD4+ Foxp3+ Treg cells in patients with RA was negatively correlated with the 
inflammation markers ESR, CRP, and total IgG, and was positively correlated with C3 
and C4 levels. B. Patients with higher circulating IL-17-producing Treg cell ratios had 
lower RA disease activity. *p < 0.05.  
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Figure 1. IL-17-producing Treg cells in peripheral blood from patients with RA and healthy controls. The 
expression of Foxp3 and IL-17 in CD4+ T cells from patients with RA and healthy controls was evaluated by 
intracellular cytokine staining and flow cytometry. A. Representative flow cytometric profile showing IL-17 
expression in CD4+ Foxp3+ Treg cells in patients with RA and healthy controls. B. Four independent 
experiments showed that the percentage of IL-17-producing Treg cells in CD4+ Foxp3+Treg cells was 
significantly higher in patients with RA (n = 12) than in healthy control subjects (n = 7). * p < 0.05. RA: 
patients with RA; HC: healthy controls. C. There is no significant correlation between IL-17-producing Treg 
cells and CD4+ Foxp3+ Treg cells in patients with RA. D. The IL-17-producing Treg cells were positively 
correlated with Th17 cells in patients with RA. E. there are higher frequency of IL-17-producing Tregs in RA 
synovial fluid than in matched peripheral blood (n=5); SF: synovial fluid; PB: peripheral blood. F. 
Distribution of IL-17 producing Treg cells in Treg fractions defined by CD45RA and Foxp3 expression. 
Numbers on the representative flow cytometry graph indicate IL-17 producing Treg numbers in that Treg 
fraction, percentages in round brackets indicate the percentages of IL-17 producing Tregs of that fraction in 
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Figure 2. IL-17-producing Treg cells display phenotypic similarities to both Th17 and Treg cells. Surface 
expression of CTLA-4, CD161, CCR6, and CD127, and intracellular expression of Foxp3 and IL-10 were 
measured in IL-17-producing CD4+ Foxp3+ Treg cells. The CD4+ Foxp3+ Treg cells and CD4+IL17+ Th17 
cells were examined by flow cytometry 5 h after stimulation with phorbol myristate acetate 
(PMA)/ionomycin. The expression levels of the surface markers or cytokines were quantified as mean 
fluorescence intensity (MFI). Data are representative of at least five independent experiments (n = 5; *p < 
0.05). A. Representative overlayed flow cytometric histograms showing expression of CTLA-4, CD161, CCR6, 
CD127, Foxp3 and IL-10 in CD4+ Foxp3+ Treg cells, IL-17-producing Treg cells and CD4+IL17+ Th17 cells; 
red histogram, CD4+ Foxp3+ Treg cells; green histogram, IL-17 producing Treg cells; blue histogram, Th17 
cells; B. The expression levels of the molecular measured above were quantified as mean fluorescence 
intensity (MFI).  
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Figure 3. Induction of peripheral CD4+ regulatory T cells into IL-17-producing CD4+Treg cells under RA 
inflammatory conditions. IL-6 and IL-23 levels in sera from patients with RA and healthy controls were 
quantified by enzyme-linked immunosorbent assay (ELISA). CD4+ T cells were stimulated with either IL-6 
or IL-23, or both in vitro in the presence of anti-CD3 and anti-CD28 mAb-coated beads, IL-2 and IL-1β. The 
expression of Foxp3 and IL-17 was determined by intracellular cytokine staining and flow cytometry. A. IL-6 
and IL-23 concentrations in sera of 39 patients with RA (RA) and 27 healthy controls (HC) were assessed by 
ELISA (*p < 0.01). B. IL-17 and Foxp3 expression levels in CD4+CD25+ Treg cells from RA patients and 
healthy controls were examined in the presence or absence of IL-6 or IL-23 in vitro with anti-CD3 and anti-
CD28 mAb-coated beads, IL-2 and IL-1β. Data are representative of three independent experiments. C. The 
frequencies of IL-17-producing Treg cells from RA patients and healthy controls were measured in the 
presence or absence of IL-6 or IL-23 in vitro. Data are from three independent experiments (*p < 0.05). D. 
Comparison of RORγt expression in CD4+CD25+ Treg cells in the presence or absence of IL-6 or IL-23 in 
vitro. Data are representative of two independent experiments.  
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Figure 4. IL-17 producing Treg cells were enriched in the CD4+CD25+CD161+ Treg subset. CD4+ CD25− 
effector T (Tresp) cells stained with CFSE were cultured alone or with IL-17 producing CD4+CD25+CD161+ 
Treg cells or CD4+CD25+CD161- Treg cells with rare IL-17 production. Tresp cells were stimulated with 
anti-CD3 and anti-CD28 mAb coated beads, and their proliferation in 5 days was determined by flow 
cytometry. A. CD4+CD25+ Treg cells could be isolated into CD4+CD25+CD161+ subset and 
CD4+CD25+CD161- subset. IL-17 producing Treg cells were enriched in the CD4+CD25+CD161+ Treg 
subset. RORgt expression was significantly elevated in CD4+CD25+CD161+ Treg cells (*p < 0.05). B. both 
of the CD4+CD25+CD161+ and CD4+CD25+CD161- Treg subsets from peripheral blood of RA patients and 
healthy controls showed comparable suppression activity on CD4+CD25- Tresp cell proliferation, while the 
suppressive activity of CD4+CD25+CD161+ and CD4+CD25+CD161- Treg subsets from RA synovial fluid 
was dramatically impaired. Data are representative of 3-5 independent experiments (*p < 0.05). RA: 
patients with RA; HC: healthy controls; Tresp: responder T cell.  
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Figure 5. Negative correlation of IL-17-producing Treg cells with RA disease activity. The correlations 
between the percentage of IL-17-producing CD4+ Foxp3+ Treg cells in circulating CD4+ Foxp3+ Treg cells 
and clinical features of patients with RA (n = 42) were analyzed by Spearman’s rank correlation test. RA 
disease activity was evaluated by the 28-joint count disease activity score (DAS28), and the IL-17-
producing CD4+ Foxp3+ Treg cell frequencies were compared between patients with high RA disease 
activity and patients with intermediate and low disease activity. A. The ratio of IL-17-producing CD4+ 
Foxp3+ Treg cells in circulating CD4+ Foxp3+ Treg cells in patients with RA was negatively correlated with 
the inflammation markers ESR, CRP, and total IgG, and was positively correlated with C3 and C4 levels. B. 
Patients with higher circulating IL-17-producing Treg cell ratios had lower RA disease activity. *p < 0.05.  
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SUPPLEMENTARY MATERIALS 
Supplementary materials and methods 
Patients and samples  
Peripheral blood samples were collected from 42 patients with RA (36 females and 
6 males) and 27 healthy donors (16 females and 11 males) at Peking University 
People’s Hospital in Beijing, China. The mean ages of the patients and healthy 
controls were 53 (range, 27–68) and 49 (range, 25–63) years, respectively. The 
disease activity score based on 28 joints (DAS28) was calculated to evaluate RA 
disease activity. All patients met the American College of Rheumatology (ACR) 1987 
revised criteria for RA classification and had active arthritis at the time of sampling 
(DAS28 ≥3.2). Patients with RA included in this study were taking methotrexate 
alone or methotrexate and one nonsteroidal anti-inflammatory drug at the time of 
sampling, and their mean DAS28 was 4.58 (range, 1.63–7.11). This study was 
approved by the Ethics Committee of Peking University People’s Hospital. 
All blood samples were processed within 1 h of collection. Peripheral blood 
mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque density gradient 
centrifugation.  
Treg cell polarization assay  
Purified CD4+CD25+ Treg cells were cultured in TexMACS GMP medium 
(Miltenyi Biotec Inc., USA), 10 IU/ml IL-2, 10ng/ml IL-1β (PeproTech, USA), and 
anti-CD3 anti-CD28 antibody coated beads (Miltenyi Biotec Inc., USA), with the 
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addition of either 20 ng/ml IL-6 or 20 ng/ml IL-23 or both for 5 days. The IL-17 and 
RORγt expression of Treg cells were determined by intracellular cytokine staining 
and flow cytometry.  
T cell proliferation and suppression assay  
To evaluate the suppressive function of IL-17 producing Treg cells, IL-17 
producing CD4+CD25+CD161+ Treg cells or CD4+CD25+CD161+ Treg cells with 
rare IL-17 production was co-cultured with purified CD4+CD25- responder T cells 
(Tresp cells) at a 1:1 ratio and a total cell density of 1 × 105 cells per well in RPMI 
1640 medium containing 10% fetal bovine serum (Invitrogen, USA). Anti-CD3 
antibody and anti-CD28 antibody coated beads (Miltenyi Biotec Inc., USA) as the 
same number as cultured cells were added to each cell-culture well to stimulate Tresp 
cell proliferation. As a positive control for T-cell proliferation, Tresp cells were 
cultured alone at 5 × 104 cells per well in the culture conditions described above. For 
the negative control, Tresp cells were cultured in the above conditions but in the 
absence of anti-CD3 and anti-CD28 antibody coated beads. On Day 5, Tresp cell 
proliferation was determined by flow cytometry.  
Cell sorting  
CD4+T cells were enriched from PBMCs by magnetic cell sorting (StemCell 
Technologies, USA). CD4+T cells were stained with PE-labeled anti-human-CD25 
antibody, FITC-labeled anti-human CD161 antibody and PE-CF594-labeled 
anti-human-CD4 antibody (BD Biosciences), and were sorted further into T responder 
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cells (Tresp, CD4+ CD25−) and two regulatory T cells subsets (CD4+CD25+CD161+ 
and CD4+CD25+CD161- Treg subsets) using a BD Aria II flow cytometer.  
Cytokine detection  
IL-6 and IL-23 in serum were measured by standard enzyme-linked 
immunosorbent assays (ELISA; R&D Systems, Minneapolis, MN, USA). 
Clinical data and inflammation marker analysis 
All patients were assessed for complete clinical data including age, sex, disease 
duration, tender joint count, swollen joint count, global visual analog scale score, 
immunoglobulins (IgG, IgM, IgA), erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), anti-keratin antibodies (AKA), anti-perinuclear factor (APF), 
anti-citrullinated peptide (anti-CCP) antibodies, rheumatoid factor (RF)-IgM, and 
RF-IgG.  
The ESR was evaluated using the Westergren method. Values of 15 mm/h for 
males and 20 mm/h for females were considered normal. CRP and immunoglobulins 
were determined using immunonephelometry. Values >7.9 mg/l for CRP were 
considered positive. Anti-CCP antibodies, RF-IgM, and RF-IgG were tested by 
ELISA, with normal ranges of 0–5 U/ml, 0–120 U/ml, and 0–110 U/ml, respectively. 
The DAS28 was calculated as previous described [19]. 
Statistical analysis 
Data were analyzed using GraphPad Prism software, and the groups were 
compared using the Mann–Whitney U test. The results are presented as bar graphs 
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with error bars representing the means ± SD. The potential correlation between the 
ratio of IL-17-producing Treg cells and clinical characteristics was examined by 
Spearman’s rank correlation test, and p values < 0.05 indicated statistical significance. 
Supplementary Table 
Supplementary Table 1. Clinical and laboratory features in 12 RA patients in Figure 1.  
Characteristics Values (%) 
Age (years) 51.36±7.56 
Men/women 4/8 
Disease duration (months) 126.33±119.63 
Tender joint count 12.027±8.003 
Swollen joint count 13.273±9.119 
DAS 28 6.018±1.595 
ESR, mm/h 60.6±34.9 
CRP, mg/l 42.5±52.4 
RF-IgM positive 10（83%） 
RF-IgG positive 4 (33%) 
AKA-positive 8(67%) 
APF-positive 8(67%) 
Anti-CCP-positive 9(75%) 
Medication methotrexate 
Clinical characteristics index were presented as mean ± SD. DAS28: 28-joint count 
Disease Activity Score; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; 
RF: rheumatoid factor; AKA: anti-keratin antibodies; APF: antiperinuclear factor; 
Anti-CCP: anti-citrullinated peptide antibody. 
 
Page 40 of 37
http://mc.manuscriptcentral.com/ard
Annals of the Rheumatic Diseases
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Confidential: For Review Only
Supplementary Figures  
Supplementary Figure 1. A representative graph of IL-17 producing Treg frequency 
in matched RA peripheral blood and synovial fluid.  
 
 
        RA Peripheral Blood                    RA Synovial Fluid 
 
 
 
Supplementary Figure 2. Correlation between IL-17 producing Treg subset from RA 
peripheral blood and RA serum Th17 polarizing cytokine levels 
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